Myriad Loses Bid To Block Ambry Cancer Tests In Patent Row

Law360, New York (March 11, 2014, 12:09 PM EDT) -- A Utah federal judge on Monday halted Myriad Genetics Inc.'s quest to block sales of Ambry Genetics Corp. cancer-testing products it claims infringe several of its patents, including five tackled in a landmark U.S. Supreme Court decision last year, ruling that Ambry had raised sufficient questions about the patents' validity.

U.S. District Judge Robert J. Shelby handed down a 106-page decision finding that Ambry's assertions about the validity of the patents in light of the high court's decision in the Association for Molecular Pathology's case against Myriad were...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

University of Utah Research Foundation et al v. Ambry Genetics


Case Number

2:13-cv-00640

Court

Utah

Nature of Suit

Patent

Judge

Robert J. Shelby

Date Filed

July 9, 2013


Case Title

In Re: BRCA1- and BRCA2- Based Hereditary Cancer Test Patent Litigation


Case Number

2:14-md-02510

Court

Utah

Nature of Suit

Patent

Judge

Robert J. Shelby

Date Filed

February 25, 2014

Law Firms

Companies

Government Agencies

Patents